GB2367748A - Use of optically pure (R)- tofisopam for treating and preventing anxiety disorders and composition thereof - Google Patents

Use of optically pure (R)- tofisopam for treating and preventing anxiety disorders and composition thereof

Info

Publication number
GB2367748A
GB2367748A GB0111739A GB0111739A GB2367748A GB 2367748 A GB2367748 A GB 2367748A GB 0111739 A GB0111739 A GB 0111739A GB 0111739 A GB0111739 A GB 0111739A GB 2367748 A GB2367748 A GB 2367748A
Authority
GB
United Kingdom
Prior art keywords
tofisopam
treating
composition
anxiety disorders
optically pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0111739A
Other languages
English (en)
Other versions
GB2367748A8 (en
GB0111739D0 (en
Inventor
Donald W Landry
Donald F Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vela Pharmaceuticals Inc
Original Assignee
Vela Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vela Pharmaceuticals Inc filed Critical Vela Pharmaceuticals Inc
Publication of GB0111739D0 publication Critical patent/GB0111739D0/en
Publication of GB2367748A publication Critical patent/GB2367748A/en
Publication of GB2367748A8 publication Critical patent/GB2367748A8/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GB0111739A 1998-10-27 1999-10-27 Use of optically pure (R)- tofisopam for treating and preventing anxiety disorders and composition thereof Withdrawn GB2367748A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10580398P 1998-10-27 1998-10-27
PCT/US1999/025040 WO2000024400A1 (en) 1998-10-27 1999-10-27 Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof

Publications (3)

Publication Number Publication Date
GB0111739D0 GB0111739D0 (en) 2001-07-04
GB2367748A true GB2367748A (en) 2002-04-17
GB2367748A8 GB2367748A8 (en) 2002-12-19

Family

ID=22307874

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0111739A Withdrawn GB2367748A (en) 1998-10-27 1999-10-27 Use of optically pure (R)- tofisopam for treating and preventing anxiety disorders and composition thereof

Country Status (16)

Country Link
EP (1) EP1124556B1 (enExample)
JP (2) JP2003522112A (enExample)
AT (1) ATE269705T1 (enExample)
AU (1) AU1451900A (enExample)
BR (1) BR9914899A (enExample)
CA (1) CA2348281A1 (enExample)
DE (1) DE69918322T2 (enExample)
DK (1) DK1124556T3 (enExample)
ES (1) ES2224751T3 (enExample)
GB (1) GB2367748A (enExample)
HK (2) HK1040908B (enExample)
IL (2) IL142803A0 (enExample)
NZ (1) NZ511744A (enExample)
PT (1) PT1124556E (enExample)
WO (1) WO2000024400A1 (enExample)
ZA (1) ZA200103376B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649607B2 (en) 2001-05-18 2003-11-18 Vela Pharmaceuticals, Inc. Compositions and methods for treating or preventing convulsions or seizures
CA2483093A1 (en) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain
US6864251B2 (en) 2002-12-03 2005-03-08 Vela Pharmaceuticals, Inc. Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines
JP2006514084A (ja) * 2002-12-03 2006-04-27 ヴェラ ファーマスーティカルズ インコーポレイテッド １−（３−ヒドロキシ−４−メトキシフェニル）−４−メチル−５−エチル−７，８−ジメトキシ−５ｈ−２，３−ベンゾジアゼピンの製薬組成物及びその用途
US7022700B2 (en) 2002-12-03 2006-04-04 Vela Pharmaceuticals, Inc. Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines
AU2003293405A1 (en) 2002-12-03 2004-06-23 Vela Pharmaceuticals, Inc. Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof
US6638928B1 (en) * 2002-12-03 2003-10-28 Vela Pharmaceuticals, Inc. Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines
CA2525273C (en) * 2003-05-16 2012-04-17 Vela Pharmaceuticals, Inc. Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (r) 2,3-benzodiazepine
EP1689408A4 (en) * 2003-12-03 2010-03-03 Vela Acquisition Corp TREATMENT OF INFLAMMATORY DISORDERS OF EPITHELIUM USING LOW DOSE 2,3-BENZODIAZEPINES
FR2870539B1 (fr) * 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
US7541355B2 (en) 2005-05-23 2009-06-02 Vela Acquisition Corporation Conversion process for 2,3-benzodiazepine enantiomers
CN102836162A (zh) * 2012-04-10 2012-12-26 珠海亿邦制药股份有限公司 一种以托非索泮为活性成分的口服固体制剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2122070A1 (de) * 1970-11-06 1972-06-08 E GY T Gyogyszervegyeszeti Gyar, Budapest 1 Veratryl 4 methyl 5 athyl 7,8 dimethoxy 2,3 diazabicyclo eckige Klam mer auf 5,4,0 eckige Klammer zu undeca pentaen (1,3,6,8,10) und seine Verwendung
HU209530B (en) * 1988-08-31 1994-07-28 Magnezitipari Muevek Rt Process for manufacturing of cromit-like, fire resistant materials

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK118660B (da) * 1966-12-09 1970-09-21 Egyt Gyogyszervegyeszeti Gyar Analogifremgangsmåde til fremstilling af 1-(3',4'-dimethoxyphenyl)-3-methyl-4-ethyl-6,7-dimethoxy-isoquinolin-N-imid.
HU178516B (en) * 1978-05-05 1982-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing enanthiomeres of 1-bracket-3,4-dimethoxy-phenyl-bracket closed-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine and pharmacologically acceptable soles of the /-/-enanthiomere

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2122070A1 (de) * 1970-11-06 1972-06-08 E GY T Gyogyszervegyeszeti Gyar, Budapest 1 Veratryl 4 methyl 5 athyl 7,8 dimethoxy 2,3 diazabicyclo eckige Klam mer auf 5,4,0 eckige Klammer zu undeca pentaen (1,3,6,8,10) und seine Verwendung
HU209530B (en) * 1988-08-31 1994-07-28 Magnezitipari Muevek Rt Process for manufacturing of cromit-like, fire resistant materials

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Agressologie, 22(1), 23-24, (1981) *
Biochem. Pharm., 32(12), 1917-20, (1983) *
CA 97:38959 & HU 209530 B *
Chirality, 1(4), 271-5, (1989) *
J. Chromatog., 709(2), 265-73, (1995) *
Martindale (1993), page 620, column 1 *
Stud. Org. Chem. (Amsterdam), 18 (Bio-Org Heterocyl.), 229-33, (1984) *

Also Published As

Publication number Publication date
EP1124556A1 (en) 2001-08-22
JP2007211028A (ja) 2007-08-23
WO2000024400A1 (en) 2000-05-04
IL142803A (en) 2006-10-05
IL142803A0 (en) 2002-03-10
CA2348281A1 (en) 2000-05-04
ZA200103376B (en) 2003-09-09
GB2367748A8 (en) 2002-12-19
DE69918322T2 (de) 2005-09-15
BR9914899A (pt) 2001-07-17
HK1040908A1 (en) 2002-06-28
AU1451900A (en) 2000-05-15
ES2224751T3 (es) 2005-03-01
HK1040908B (en) 2005-04-22
NZ511744A (en) 2004-04-30
DK1124556T3 (da) 2004-10-11
JP2003522112A (ja) 2003-07-22
HK1046500A1 (zh) 2003-01-17
DE69918322D1 (de) 2004-07-29
PT1124556E (pt) 2004-10-29
EP1124556B1 (en) 2004-06-23
ATE269705T1 (de) 2004-07-15
GB0111739D0 (en) 2001-07-04

Similar Documents

Publication Publication Date Title
DK0867178T3 (da) Non-allosteriske GABA A agonister til behandling af søvnforstyrrelser
PL345275A1 (en) Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
NZ332780A (en) Substituted amines for the treatment of neurological and neuropsychiatric disorders
DE69914726D1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
GB2367748A (en) Use of optically pure (R)- tofisopam for treating and preventing anxiety disorders and composition thereof
BG106065A (en) Method for the treatment of neurological or neuropsychiatric disorders
UA41355C2 (uk) Засіб для лікування нейро-сніду
DK0786991T3 (da) Polyaminforbindelsre til behandling af proliferative karsygdomme
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
HUP0103842A3 (en) Method for the treatment of mania and bipolar disorder
AU4238693A (en) Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
EP0727994A4 (en) ANTIPYRETIC AND ANALGESIC METHODS AND COMPOSITIONS CONTAINING OPTICALLY PURE ETODOLIC ACID
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa
HU9902668D0 (en) Compounds with growth hormone releasing properties
PL338673A1 (en) Application of fanquinone in treating alzheimer disease
NZ324615A (en) Method for treating autism using olanzapine
NO984189D0 (no) Fremgangsmåte for behandling av bipolar forstyrrelse
NZ335493A (en) Substituted 4-(6-fluoro-(1h)-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders
AP2000001963A0 (en) Paroxetine ascorbate.
AU5330599A (en) Methods and compositions for treating and preventing certain psychiatric and medical disorders using moclobemide
DK0900085T3 (da) Behandling af overdreven aggression med olanzapin
CA2387394A1 (en) Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
IL144852A0 (en) Use of fluorinated triazoles for treating pain and affective or attention disorders
DE69941134D1 (de) Verwendung von R (+)- g(a)-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol zur Behandlung von Schlafstörungen
UA36261A (uk) Спосіб лікування простої шизофренії з суїцидальною поведінкою

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1046500

Country of ref document: HK